Electra Therapeutics, Inc. (ETRA) shareholders
Close on Nov 17, 2026Market cap $524.94MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vii LLC (8.20%) | 6,885,170 | 11.00% | 13D (active) | Sep 21, 2026 |
| Dr. Beth C. Seidenberg Joint filing with Westlake BioPartners Fund I, L.P. (5.60%), Westlake BioPartners GP I, LLC (5.60%) | 6,347,539 | 10.10% | 13G (passive) | Sep 30, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (8.70%), Redmile Biopharma Investments II, L.P. (7.60%) | 5,462,881 | 8.70% | 13G (passive) | Sep 21, 2026 |
| LSP 7 Management B.V. Joint filing with LSP 7 Cooperatief U.A. (6.00%) | 3,795,281 | 6.00% | 13G (passive) | Sep 21, 2026 |
Top institutional holders
13F holdings as of Mar 31, 2026
| Holder | Shares | % of ETRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kentucky Retirement Systems | 23,712 | – | $466.00K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2021 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2021 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q1 2021 | 0 | 0M | 0 / 0 | 0 / 2 | 0M | 0M |
| Q4 2020 | 2 | 0M | 1 / 0 | 0 / 407 | 0M | 204M |
| Q3 2020 | 410 | 204M | 43 / 122 | 173 / 40 | 16M | 25M |
| Q2 2020 | 407 | 213M | 57 / 110 | 189 / 61 | 30M | 33M |
| Q1 2020 | 412 | 217M | 64 / 119 | 184 / 119 | 63M | 59M |
| Q4 2019 | 473 | 213M | 83 / 142 | 194 / 69 | 38M | 34M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Quehuong (Kathy) Dong | President & CEO, Director | 455,484 | Sep 21, 2026 |
| Gary S. Koe | Chief Technical Officer | 63,656 | Sep 21, 2026 |
| Graham Parry | Chief Scientific Officer | 85,504 | Sep 21, 2026 |
| David J. Tucker | Principal Accounting Officer | – | Sep 18, 2026 |
| Christopher William Clark | Chief Financial Officer | – | Sep 18, 2026 |
| Kim-Hien Dao | Chief Medical Officer | – | Sep 18, 2026 |
| Carl L. Gordon | Director, 10% owner | 2,194,579 | Nov 10, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | – | Nov 10, 2026 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | 5,126,891 | Nov 10, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 2,194,579 | Nov 10, 2026 |
| Nancy Stagliano | Director | 255,635 | Sep 21, 2026 |
| Matthew K. Fust | Director | – | Sep 18, 2026 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners GP I, LLC | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners GP II, LLC | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners Fund II, L.P. | 10% owner | 2,820,403 | Sep 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Carl L. Gordon Director, 10% owner | Nov 10, 2026 | Buy | +2,000 | $8.45 | $16.90K | 2,194,579 |
| Carl L. Gordon Director, 10% owner | Nov 10, 2026 | Buy | +20,700 | $8.45 | $174.91K | 5,255,278 |
| Advisors Llc Orbimed Director, 10% owner | Nov 10, 2026 | Buy | +2,000 | $8.45 | $16.90K | 2,194,579 |
| Advisors Llc Orbimed Director, 10% owner | Nov 10, 2026 | Buy | +20,700 | $8.45 | $174.91K | 5,255,278 |
| Carl L. Gordon Director, 10% owner | Nov 9, 2026 | Buy | +16,000 | $8.24 | $131.84K | 2,192,579 |
| Carl L. Gordon Director, 10% owner | Nov 9, 2026 | Buy | +4,000 | $8.24 | $32.96K | 5,234,578 |
| Advisors Llc Orbimed Director, 10% owner | Nov 9, 2026 | Buy | +16,000 | $8.24 | $131.84K | 2,192,579 |
| Advisors Llc Orbimed Director, 10% owner | Nov 9, 2026 | Buy | +4,000 | $8.24 | $32.96K | 5,234,578 |
| Carl L. Gordon Director, 10% owner | Nov 6, 2026 | Buy | +39,600 | $7.85 | $310.86K | 2,176,579 |
| Carl L. Gordon Director, 10% owner | Nov 6, 2026 | Buy | +9,816 | $7.85 | $77.06K | 5,230,578 |
| Advisors Llc Orbimed Director, 10% owner | Nov 6, 2026 | Buy | +39,600 | $7.85 | $310.86K | 2,176,579 |
| Advisors Llc Orbimed Director, 10% owner | Nov 6, 2026 | Buy | +9,816 | $7.85 | $77.06K | 5,230,578 |
| Carl L. Gordon Director, 10% owner | Nov 5, 2026 | Buy | +125,200 | $7.31 | $915.21K | 2,136,979 |
| Carl L. Gordon Director, 10% owner | Nov 5, 2026 | Buy | +30,891 | $7.31 | $225.81K | 5,220,762 |
| Advisors Llc Orbimed Director, 10% owner | Nov 5, 2026 | Buy | +125,200 | $7.31 | $915.21K | 2,136,979 |
| Advisors Llc Orbimed Director, 10% owner | Nov 5, 2026 | Buy | +30,891 | $7.31 | $225.81K | 5,220,762 |
| Carl L. Gordon Director, 10% owner | Nov 4, 2026 | Buy | +20,000 | $7.07 | $141.40K | 2,011,779 |
| Carl L. Gordon Director, 10% owner | Nov 4, 2026 | Buy | +5,000 | $7.07 | $35.35K | 5,189,871 |
| Carl L. Gordon Director, 10% owner | Nov 4, 2026 | Buy | +37,100 | $7.78 | $288.64K | 1,991,779 |
| Carl L. Gordon Director, 10% owner | Nov 4, 2026 | Buy | +9,267 | $7.78 | $72.10K | 5,184,871 |
| Advisors Llc Orbimed Director, 10% owner | Nov 4, 2026 | Buy | +20,000 | $7.07 | $141.40K | 2,011,779 |
| Advisors Llc Orbimed Director, 10% owner | Nov 4, 2026 | Buy | +5,000 | $7.07 | $35.35K | 5,189,871 |
| Advisors Llc Orbimed Director, 10% owner | Nov 4, 2026 | Buy | +37,100 | $7.78 | $288.64K | 1,991,779 |
| Advisors Llc Orbimed Director, 10% owner | Nov 4, 2026 | Buy | +9,267 | $7.78 | $72.10K | 5,184,871 |
| Carl L. Gordon Director, 10% owner | Nov 3, 2026 | Buy | +98,600 | $7.88 | $776.97K | 1,954,679 |
| Carl L. Gordon Director, 10% owner | Nov 3, 2026 | Buy | +24,400 | $7.88 | $192.27K | 5,175,604 |
| Carl L. Gordon Director, 10% owner | Nov 3, 2026 | Buy | +97,800 | $7.84 | $766.75K | 1,856,079 |
| Carl L. Gordon Director, 10% owner | Nov 3, 2026 | Buy | +24,313 | $7.84 | $190.61K | 5,151,204 |
| Advisors Llc Orbimed Director, 10% owner | Nov 3, 2026 | Buy | +98,600 | $7.88 | $776.97K | 1,954,679 |
| Advisors Llc Orbimed Director, 10% owner | Nov 3, 2026 | Buy | +24,400 | $7.88 | $192.27K | 5,175,604 |
| Advisors Llc Orbimed Director, 10% owner | Nov 3, 2026 | Buy | +97,800 | $7.84 | $766.75K | 1,856,079 |
| Advisors Llc Orbimed Director, 10% owner | Nov 3, 2026 | Buy | +24,313 | $7.84 | $190.61K | 5,151,204 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Buy | +333,333 | $15.00 | $5.00M | 5,126,891 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +1,087,934 | – | – | 3,090,244 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,758,279 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +758,279 | – | – | 758,279 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +1,703,314 | – | – | 4,793,558 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +2,002,310 | – | – | 2,002,310 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +758,279 | – | – | 758,279 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +2,002,310 | – | – | 2,002,310 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +1,087,934 | – | – | 3,090,244 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,758,279 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +1,703,314 | – | – | 4,793,558 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Buy | +333,333 | $15.00 | $5.00M | 5,126,891 |
| Gary S. Koe Chief Technical Officer | Sep 21, 2026 | Conversion | +63,656 | – | – | 63,656 |
| Graham Parry Chief Scientific Officer | Sep 21, 2026 | Conversion | +85,504 | – | – | 85,504 |
| Quehuong (Kathy) Dong President & CEO, Director | Sep 21, 2026 | Conversion | +455,484 | – | – | 455,484 |
| Nancy Stagliano Director | Sep 21, 2026 | Conversion | +255,635 | – | – | 255,635 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 2 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Electra Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 506,125 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?